Gal Cohen - Chief Executive Officer
Lior Rosenberg - Chief Medical Officer
Ronit Koren - VP Clinical Affairs
Andrey Kon - VP Plant Manager
Sharon Malka - Head of Finance
Eilon Asculai - VP R&D
Nimrod Leuw – Director QA
Smadar Nestor – Director RA
Gal Cohen, B.Sc., MBA – Chief Executive Officer
Mr. Cohen had been serving as MediWound’s CEO since November 2006.
Prior to joining MediWound, Mr. Cohen held several management positions at Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) as Director of Strategic Business Planning & New Ventures, Projects Manager for the Global Products Division and Team Leader at Teva’s Corporate Industrial engineering department. During this period, he led various business transactions and alliances with start-up companies and academic institutions, was the Project Manager of the launch of Copaxone®, Teva’s flagship innovative product, in numerous countries as well as developed various medical devices.
Mr. Cohen holds a cum laude B.Sc. in Industrial Engineering & Management from the Technion -Israel’s Institute of Technology, and a cum laude MBA from Tel-Aviv University.
Lior Rosenberg, M.D. - Chief Medical Officer
Prof. Rosenberg was one of the founders of MediWound and has been serving as MediWound Chief Medical Officer since its inception. Prof. Rosenberg is also a member of the Board of Directors of MediWound.
Prof. Rosenberg is the head of the Department of Plastic Surgery at Soroka University Medical Center in Beer Sheva, heads the unit for Cleft Lip Palate & Craniofacial deformities at Meir Medical Center, Kfar Saba, and is a Professor of Medicine at the Ben-Gurion University Medical School in Beer Sheva. His years of pioneering work with the product and his expertise and extensive personal ties with key opinion leaders in the field of burns and wound care form the clinical basis of MediWound’s development program. Prof. Rosenberg has given more than 60 presentations relating to Debrase® at international conferences and published numerous peer reviewed papers, 2 of the papers were specifically about Debrase®.
Ronit Koren, Ph.D. - VP Clinical Affairs
Dr. Koren has been directing the clinical research department of MediWound since its inception.
Dr. Koren had more than 20 years of experience in managing clinical trials in Bio-Technology General (NASDAQ: SVNT). She has successfully managed the conduct of and has completed clinical trials worldwide with biotech products such as recombinant proteins, vaccines and ophthalmic and orthopedic devices.
Andrey Kon, M.Sc. – VP Plant Manager
Mr. Kon has been serving as Head of Production of MediWound since its inception.
Mr. Kon has over 15 years of experience in the biotech industry. Prior to founding MediWound he served as head of production of Omrix pharmaceuticals Inc (NASDAQ: OMRI).
Mr. Kon holds a M.Sc. in Biotechnology from St. Petersburg pharmaceutical institute.
Sharon Malka, C.P.A., MBA – Head of Finance
Mr. Malka joint MediWound as Head of Finance in April 2007.
Prior to joining Mediwound, he served as a partner at Varinace Economic Consulting Ltd., a full-service consulting firm and as a senior manager at Kesselman Corporate Finance, a division of PricewaterhouseCoopers Global Network (PwC). Mr. Malka’s experience includes business and economic consulting for a number of public companies regarding valuations, SEC filing, feasibility studies and financial/strategic planning.
Mr. Malka holds a B.Sc. in Business Administration from the Business Management College, Israel and an MBA from Bar Ilan University, Israel.
Eilon Asculai, Ph.D, MBA - VP R&D
Dr. Asculai serves as MedWound's Vice President, R&D since July 2007. Prior to joining Mediwound, Dr. Asculai was the Senior Director of the Pharmaceutical R&D at Perrigo Israel Pharmaceuticals (NASDAQ/TASE: PRGO). In this position he managed all pharmaceutical development activities from initiation to submission. Dr. Asculai led a considerable senior scientific and technical staff in the process of development of generic and innovative products. During his service at Perrigo (formerly Agis), the pharmaceutical R&D specialized mainly in topical and dermatological products and became one of the world's leading R&D groups in this field. Prior to his last position, Dr. Asculai served for nine years, in various management positions in Perrigo in Pharmaceutical R&D.
Dr. Asculai holds B.Sc., M.Sc. (Summa cum Laude), Ph.D in Medical Sciences, and MBA (hons.) degrees, all from the Ben-Gurion University.
Nimrod Leuw, B.Sc. - Director of Quality Assurance & Control
Mr. Leuw has been serving as Mediwound's Director of Quality Assurance & Control since November 2007.
Mr. Leuw has over 14 years of experience in the field of quality in the pharmaceutical and biotechnology industry.
Prior joining MediWound, he served for 3 years as Director of Quality Assurance & Control at Prochon Biotech company and for 11 years at Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) where he was a validation department manager as well as served in several previous positions in Quality Assurance.
Mr. Leuw holds a B.Sc. in Chemistry from Ben Gurion University, Israel
Smadar Nestor M.Sc. - Director of Regulatory Affairs
Ms. Nestor serves as MediWound's Director of Regulatory Affairs since January 2008.
Ms. Nestor has over 10 years of experience in the field of international regulatory affairs. Prior to joining Mediwound, she was responsible for the planning and coordinating of key regulatory activities in the pharmaceutical industry while working for Collgard Biopahrmaceuticals Ltd as a Regulatory Affairs Manager and for Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) as a Regulatory Affairs Product Manager.
Ms. Nestor holds a B.Sc. in Pharmacy (School of Pharmacy, The Hebrew University of Jerusalem) and a M.Sc., with distinction, in Human Genetics from the Faculty of Medicine, Tel Aviv University, Israel.
